Plain-English translation of NCT06400771 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a Phase 1 trial testing a new medication called in healthy volunteers. Researchers want to understand how safe this medication is, how well people tolerate it, and how the body processes it when given as a single intravenous (IV) infusion. Because this is very early-stage research, the trial starts with the lowest possible dose and only increases doses if the medication proves safe.
This medication is being developed to help treat serious liver problems, including rejection after liver transplant and fatty liver disease. Before doctors can test it in patients with these conditions, researchers must first confirm that the treatment is safe and well-tolerated in healthy people.
You will have a screening visit within 4 weeks before the trial starts. On the day before treatment, you'll check into the hospital clinical trial center and fast overnight. On Day 1, you'll receive the medication as a 30-minute IV infusion, then stay hospitalized for 4 days while researchers monitor you. After discharge, you'll return to the clinic for follow-up visits on days 8, 11, 15, 22, and 29 to have blood drawn and answer health questions. The entire trial lasts about one month.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
South Korea
Phase
Safety & dosing
Sponsor
Seoul National University Hospital
Enrollment target
~12 participants
Started
June 2024
Primary completion
December 2024
Age range
19 Years – 55 Years
Sex
Male only
Last updated on clinicaltrials.gov in June 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Dongkyu Han, Ph.D.
Department of Surgery, Seoul National University College of Medicine